Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and … – Nasdaq
|
Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and …
Nasdaq NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell ("CAR … Fortress Biotech Announces Positive Clinical Data From Fortress … |
